NeuroSense Therapeutics Ltd. Ordinary Shares (NRSN)

FairStock Score: 20/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses with durable competitive advantages, honest accounting, and a margin of safety. NeuroSense is a clinical-stage biotech with 17 employees and a lead candidate, PrimeC, in Phase 2b/3 for ALS. That is a high-risk, binary research effort, not a proven business. The figures tell a stark story: FairStock's calculations show a P/E of -0.07, ROE of -2174.98%, ROCE of -247.30%, a Piotroski F-Score of 0/9, and an Altman Z-Score of -61.21. Those are not the marks of financial strength; they point to a company consuming capital with no profits and no reported revenue growth or profit growth in the provided data. There is no meaningful moat here—no marketed product, no pricing power, no recurring revenue, and only a clinical pipeline. Valuation is almost impossible in the Graham sense because earnings are negative and P/B is N/A. At $3.49 on 2026-10-13, the $25.4M market cap rests on hopes for trial success, not on demonstrated earning power. The 52-week range of $0.25 to $7.50 and beta of 1.64 confirm an extremely volatile, speculative equity. Growth is entirely contingent on clinical and regulatory milestones. With only 0 years of filed results and no Lynch category because three years are needed, there is insufficient history to judge management's capital allocation. This may be a lottery ticket, but it is not a Buffett-style compounder. I would require a substantial margin of safety and evidence of financial staying power, neither of which appears in these numbers.

In plain English: NeuroSense Therapeutics is a small clinical-stage biotechnology company with 17 employees, developing an oral treatment for neurodegenerative diseases, mainly ALS. The business looks weak by the numbers: it is not profitable, has negative returns, and a very weak financial score. The stock price looks speculative rather than cheap or fair because there are no meaningful sales or profits to anchor it.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer